Abiopharma

🔍 Schwab Andrew J. (Executive)

Company: Skye Bioscience, Inc. (SKYE)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Sold 45,090 shares of Common Stock at $0.38 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,411,974.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,830 shares of Common Stock at $0.38 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,663.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 253,080 shares of Common Stock at $0.38 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,914,126.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 10,255 shares of Common Stock at $0.35 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,401,719.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 409 shares of Common Stock at $0.35 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,254.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 57,476 shares of Common Stock at $0.35 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,856,650.00 | transaction_form_type: 4 | Footnotes: F5, F4
• Sold 1,159 shares of Common Stock at $0.32 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,400,560.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 46 shares of Common Stock at $0.32 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,208.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 6,495 shares of Common Stock at $0.32 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,850,155.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F3: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F4: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.